The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 9 results:
[ Author(Desc)] Title Type Year
Filters: Author is Makras, Polyzois  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Makras, P., Anastasilakis A. D., Polyzos S. A., Bisbinas I., Sakellariou G. T., & Papapoulos S. E. (2011).  No effect of rosuvastatin in the zoledronate-induced acute-phase response.. Calcif Tissue Int. 88(5), 402-8.
Makras, P., Polyzos S. A., & Anastasilakis A. D. (2016).  Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.. J Clin Endocrinol Metab. 101(9), L89-90.
Makras, P., Yavropoulou M. P., Polyzos S. A., Papapoulos S. E., Georgakopoulou D., Papatheodorou A., et al. (2023).  The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.. Osteoporos Int.
Makras, P., Polyzos S. A., Papatheodorou A., Kokkoris P., Chatzifotiadis D., & Anastasilakis A. D. (2013).  Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.. Clin Endocrinol (Oxf). 79(4), 499-503.
Makras, P., Appelman-Dijkstra N. M., Papapoulos S. E., van Wissen S., Winter E. M., Polyzos S. A., et al. (2021).  The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation.. J Clin Endocrinol Metab.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Kanakis G., Schini M., et al. (2012).  Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.. J Clin Endocrinol Metab. 97(4), E618-21.
Makras, P., Babis G. C., Chronopoulos E., Karachalios T., Kazakos K., Paridis D., et al. (2020).  Experience gained from the implementation of the fracture liaison service in Greece.. Arch Osteoporos. 15(1), 12.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Papatheodorou A., & Kaltsas G. A. (2012).  Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?. Mol Ther. 20(1), 6-7.
Makras, P., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Anastasilakis A. D. (2020).  The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.. Bone. 138, 115478.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.